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Heightened DJ-1 (Park7) expression is associated with a re-
duction in chemotherapeutic-induced cell death and poor
prognosis in several cancers, whereas the loss of DJ-1 function
is found in a subgroup of Parkinson disease associated with
neuronal death. This study describes a novel pathway by which
DJ-1 modulates cell survival. Mass spectrometry shows that
DJ-1 interacts with BBS1, CLCF1, MTREF, and Cezanne/
OTUD7B/Za20d1. Among these, Cezanne is a known deubiq-
uitination enzyme that inhibits NF-B activity. DJ-1/Cezanne
interaction is confirmed by co-immunoprecipitation of over-
expressed and endogenous proteins, maps to the amino-termi-
nal 70 residues of DJ-1, and leads to the inhibition of the deu-
biquitinating activity of Cezanne. Microarray profiling of
shRNA-transduced cells shows that DJ-1 and Cezanne regulate
IL-8 and ICAM-1 expression in opposing directions. Similarly,
DJ-1 enhances NF-B nuclear translocation and cell survival,
whereas Cezanne reduces these outcomes. Analysis of mouse
Park7/ primary cells confirms the regulation of ICAM-1 by
DJ-1 and Cezanne. As NF-B is important in cellular survival
and transformation, IL-8 functions as an angiogenic factor and
pro-survival signal, and ICAM-1 has been implicated in tumor
progression, invasion, and metastasis; these data provide an
additional modality by which DJ-1 controls cell survival and
possibly tumor progression via interaction with Cezanne.
Lung cancer is the leading cause of cancer-related mortality
in the world. It is estimated that over 215,000 new cases were
diagnosed in the United States in 2008 alone (1). Of the two
major types of lung cancer, 85% are non-small cell lung carci-
nomas (NSCLC)2 (2). With NSCLC, the best chance for a long
term cure is surgery. Unfortunately, 70% of NSCLC patients
are initially contraindicated for surgery due to locally invasive
or metastatic disease (3). For these patients, the current treat-
ment options are a combination of chemotherapy and radia-
tion. With treatment, NSCLC patients have a 5-year survival
rate of 15%. It is therefore imperative to investigate new path-
ways to target in NSCLC. Our work in the H157 NSCLC
squamous cell line has focused on the role of DJ-1.
DJ-1 is associated with a spectrum of human disease. Loss
of DJ-1 activity, due to inactivation by mutation or genetic
deletion, causes early onset Parkinson disease with high pen-
etrance (4). Due to the protective effects of DJ-1 against toxic
insults, this association is hypothesized to be due to a protec-
tive role of DJ-1 in dopaminergic neurons of the substantia
nigra (5–7). As loss of DJ-1 activity leads to neuronal cell
death, increased DJ-1 activity can promote cell survival, lead-
ing to its association with human malignancies. Initial re-
search on the role of DJ-1 in cancer showed that although
DJ-1 can weakly transform cells alone, it can act synergisti-
cally in combination with Ras (8). DJ-1 is highly expressed in a
number of cancer types including acute leukemia, breast,
prostate, ovarian, and thyroid cancer, and NSCLC and is asso-
ciated with tumor progression in esophageal and cervical can-
cer (9–15). Our laboratory and others have shown that in-
creased DJ-1 expression confers protection against toxic
insults including oxidative and endoplasmic reticulum stress,
proteasome inhibition, and chemotherapeutic agents (16–18).
This protection is partially mediated by the ability of DJ-1 to
inhibit p53 and Phosphatase and Tensin homolog (PTEN), an
inhibitor of the PI3K cell survival pathway, and to positively
regulate the Nrf2 detoxification pathway (15, 19, 20). Here we
examine a novel pathway in which DJ-1 binds to and inhibits
Cezanne, a negative regulator of the cell survival-associated
transcription factor NF-B.
Cezanne is a member of the A20 family of deubiquitination
enzymes (21). Similar to A20, Cezanne has been shown to
inhibit NF-B through modulation of the ubiquitination state
of two of its positive regulators, RIP-1 and TRAF6 (21, 22).
Cezanne is implicated in cancer biology as a 93-kb sequence
containing Cezanne was shown to be duplicated in acute lym-
phoblastic leukemia and Burkitt lymphoma (23). Although
the precise role of Cezanne in cancer is unknown, its inhibi-
tion of NF-B would suggest that Cezanne may act as a tumor
suppressor.
Although typically associated with regulating the inflam-
matory response to infection or injury, NF-B subunits are
constitutively activated in a number of human carcinomas
(24–26). This family of transcription factors plays a role in
* This work was supported by the Lineberger Comprehensive Cancer Cen-
ter, the University Cancer Research Fund, and UNC Cancer Cell Biology
Training Grant 5T32CA071341-15. This work was also supported by a
grant from the Crohn’s and Colitis Foundation of America (to B. K. D.).
□S The on-line version of this article (available at http://www.jbc.org) con-
tains supplemental Figs. S1 and S2.
1 To whom correspondence should be addressed: 450 West Dr., LCCC 22-
004 CB#7295, Chapel Hill, NC 27599. Tel.: 919-966-5538; Fax: 919-966-
8212; E-mail: jenny_ting@med.unc.edu.
2 The abbreviations used are: NSCLC, non-small cell lung carcinomas;
ICAM-1, intercellular adhesion molecule 1; MEF, mouse embryonic fibro-
blast; Nrf2, nuclear factor (erythroid-derived 2)-like 2; Q-TOF, quadrupole-
time-of-flight; IsoT, Isopeptidase T.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 6, pp. 4098 –4106, February 11, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
4098 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 6 • FEBRUARY 11, 2011
cancer cell survival, angiogenesis, invasion, progression, and
metastasis. Two important targets of NF-B-mediated tran-
scription in relation to cancer are interleukin 8 (IL-8) and in-
tercellular adhesion molecule 1 (ICAM-1). These two proteins
are involved in the homing and extravasation of neutrophils
from the blood into inflamed tissues but have additional func-
tions in cancer biology. IL-8 expression has been associated
with cancer progression, invasion, angiogenesis, and metasta-
sis (27–33). It is also secreted by certain NSCLC cell lines,
including H157 cells, in response to Paclitaxel treatment, acti-
vating a pro-survival-positive feedback loop via signaling
through the CXCR1 receptor (34, 35). Blockade of IL-8 bind-
ing to its receptor causes a decrease in tumor size, angiogene-
sis, tumor growth, and metastasis while promoting cancer cell
apoptosis (36). ICAM-1 is highly expressed in multiple human
cancers as well (37–39). Although it has not been associated
with effects on cancer cell survival, ICAM-1 has been linked
to both tumor progression and metastasis through its ability
to mediate cell adhesion and extravagation (33, 40, 41).
In this study, we identify Cezanne as a binding partner of
DJ-1. This interaction can be mediated by the amino terminus
of DJ-1 and leads to the inhibition of the deubiquitinating
activity of Cezanne in vitro. Microarray analysis on H157 cells
shows that DJ-1 and Cezanne shRNAs regulate IL-8 and
ICAM-1 gene expression, albeit in opposing directions. DJ-1
and Cezanne shRNA treatments also result in reciprocal phe-
notypes in chemotherapeutic-induced cell death and NF-B
nuclear localization in vitro. Finally, we analyzed ICAM-1 ex-
pression in Park7/ mouse embryonic fibroblasts (MEF) to
verify that this pathway is intact in a primary cell line. These
findings identify a novel pathway through which DJ-1 modu-
lates a number of critical aspects of cancer cell biology as well
as uncovering a potential role of DJ-1 in leukocyte migration
and inflammation. This work emphasizes the importance of
future research on pharmacologic inhibitors of the DJ-1/Cez-
anne pathway and the role of DJ-1 in cancer biology in vivo.
EXPERIMENTAL PROCEDURES
Cell Culture, Treatments, and Plasmid Constructs—H157
cells were grown in RPMI 1640 (Invitrogen) with 10% FCS
(HyClone). HEK293T cells and MEFs were grown in high glu-
cose DMEM (Invitrogen) with 10% FCS. MEFs were isolated
from 13.5-day embryos and used within three passages from
initial isolation. All mammalian cell cultures were incubated
at 37 °C with 5% CO2 in the presence of penicillin and strep-
tomycin. H2O2 (Sigma) was added to cells at 100 M for 1 h.
TNF (eBioscience) was used at 5–50 ng/ml for 6 h before
sample harvest. For cell death assays, Paclitaxel and U0126
(Sigma) reconstituted in dimethyl sulfoxide (DMSO) were
used at 500 nM and 10 M, respectively.
Human Cezanne ORF was subcloned into the V5/His-
tagged pcDNA3.1D-Topo plasmid (Invitrogen) using the
primers 5-CAC CAT GAC CCT GGA CAT GGA TGC
TG-3 and 5-GAA CCT GTG CAC CAG GAG CT-3. Direc-
tionality and expression were verified by sequencing and im-
munoblot analysis, respectively. The FLAGTM-DJ-1 construct
was generously given to us by Y. Hod (12). The point and
truncation mutants of FLAG-DJ-1 were produced using
QuikChange mutagenesis (Stratagene) and verified by se-
quencing. MEF cultures were transfected using Lipofectamine
2000 (Invitrogen) at a 4:1 reagent to DNA ratio, and
HEK293T cultures were transfected using FuGENE 6 (Roche
Applied Science) at a 3:1 ratio as per the manufacturer’s
instructions.
Q-TOF Mass Spectrometry—Park7/ MEFs were trans-
fected with either FLAG-DJ-1 or C016A-FLAG. After H2O2
or vehicle control treatment, samples were lysed in 0.5% Tri-
ton X-100 lysis buffer and immunoprecipitated with anti-
FLAGM2-agarose (Sigma). Samples were eluted with FLAG
peptide and desalted using a C4 reverse-phase media-loaded
micropipette tip (Millipore). The desalted proteins were
eluted from the tip using a solution of 80% methanol with
0.1% formic acid and then lyophilized. After reconstitution in
25 mM ammonium bicarbonate, the protein samples were
enzymatically digested with sequencing grade trypsin (Pro-
mega). The peptides were analyzed by nano-LC-MS/MS using
a Waters API-US Q-TOF, equipped with a Waters capLC sys-
tem and a 75-m inner diameter  15-cm PepMap C18 col-
umn (Dionex). The Q-TOF data were processed using the
Waters MassLynx and ProteinLynx software and searched
against the NCBInr mouse database for possible protein
matches using the Mascot (Boston, MA) database search en-
gine. The search parameters include a peptide mass tolerance
of  200 ppm, fragment mass tolerance of  0.2 Da, and tryp-
sin as the enzyme with one possible missed cleavage.
Lentiviral Vector Construction and Production—Oligonu-
cleotides containing 19-mers targeting DJ-1 (5-GAC CCA
GUA CAG UGU AGC C-3), human Cezanne (5-GAT CAT
GAA TGG AGG AAT A-3 and 5-GCA GCA AGC TCA
AGA AGA A-3), mouse Cezanne (5-GGC GGA AGG AGA
AGT CAA A-3), or non-silencing controls (5-GAC GCT
GAA GAC TCT TGG C-3, 5-GAT GAA GTA AGC ACG
TAA A-3, and 5-GCA CCT ACC ACT ACA TGT A-3)
with appropriate start (5-TCC GCT CGA GAA AAA-3),
loop (5-TCT CTT GAA-3), antisense, and termination (5-
GGT GTT TCG TCC TTT CCA CAA GAT ATA TAA AGC
C-3) sequences were synthesized (Integrated DNA Technol-
ogies) and cloned into FG12 vectors (42). Lentiviral particles
were then produced by co-expressing the FG12 constructs
with lentiviral VSVg, Rev, and GAGPOL vectors in HEK293T
cells (42, 43). Lentiviral transduction and gene expression
were assessed by GFP fluorescence and semiquantitative RT-
PCR for DJ-1, Cezanne, and -actin, respectively.
Affymetrix Analysis—RNA was harvested from H157 cells
transduced with DJ-1, Cezanne, or mutant control shRNA
lentivirus using an RNeasy kit (Qiagen). RNA quality was as-
sessed by an Agilent bioanalyzer (Agilent). CDNA production,
biotinylated cRNA generation and fragmentation, array hy-
bridization, washing, staining, and scanning were done as
shown previously (19). Final filtering and analysis of the
GeneChip Human Gene 1.0 ST array (Affymetrix) raw data
were performed using GeneSpring GX (Agilent). We elimi-
nated dots with 20 percentile intensity, averaged the dot
intensities of the three mutant control samples, and calcu-
lated -fold changes on hits shared between the DJ-1 and
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Cezanne shRNA-treated experimental groups. The -fold
change cut off was set at 1.7.
In Vitro Deubiquitination Assay—Vectors for production of
recombinant DJ-1 and Cezanne were produced by cloning
DJ-1 and CezanneORFs into the His6-tagged pQE-82L (Qia-
gen) and pET101D (Invitrogen) vectors, respectively. Recom-
binant protein was produced in BL21 star (Invitrogen) Esche-
richia coli stimulated with 1 mM isopropyl -D-1-
thiogalactopyranoside (Sigma). The bacteria were lysed by
sonication in the presence of hen egg lysozyme (Sigma) and
Benzonase (Novagen), and the target recombinant proteins
were purified using a nickel-nitrilotriacetic acid agarose (In-
vitrogen) column. Recombinant protein expression and purity
were assessed by Coomassie Blue staining and immunoblot.
The K48-linked ubiquitin chains (Ub2–16) and recombinant
IsoT were purchased (BIOMOL). Each sample containing 1
g of ubiquitin chains and indicated proteins was incubated
at 37 °C for 6 h in deubiquitination buffer (50 mM Hepes, pH
7.8, 0.5 mM EDTA, 0.01% Brij 35, 3 mM DTT), and ubiquitin
chain degradation was assessed by immunoblot.
Immunoblot Analysis and Immunoprecipitation—Immuno-
blot analysis was performed as reported previously (19). Pri-
mary antibodies used for blotting were anti-FLAGM2-HRP
(Sigma), anti-V5-HRP (Invitrogen), anti--actin-HRP C11
(Santa Cruz Biotechnology), Cezanne rabbit polyclonal, DJ-1
rabbit polyclonal, HDAC2 (Santa Cruz Biotechnology), anti-
ubiquitin P4D1 (Santa Cruz Biotechnology), and anti-
ICAM-1 EP1442Y (Abcam). Goat anti-mouse-HRP and goat
anti-rabbit HRP antibodies were used as secondary antibodies
(Santa Cruz Biotechnology). Nuclear and cytoplasmic frac-
tionation was performed using the NE-PER fractionation kit
(Pierce) as per the manufacturer’s instructions. Samples for
immunoprecipitation were lysed in 0.5% Triton X-100 lysis
buffer, cleared by centrifugation, and precipitated overnight
with appropriate beads at 4 °C. V5-tagged and FLAG-tagged
proteins were precipitated using V5- (Invitrogen) or FLAG-
(Sigma) agarose, respectively, whereas endogenous DJ-1 was
precipitated using DJ-1 4D1.3 mouse monoclonal antibody
and protein A/G beads (Pierce). After overnight incubation,
the samples were washed in lysis buffer and eluted in 2 LDS
loading buffer with DTT at 90 °C. Input and eluate samples
were then analyzed by immunoblot for expression and pro-
tein association.
Real-time and Reverse Transcriptase Semiquantitative PCR—
Real-Time PCR was performed using an ABI 7900HT PCR
system (Applied Biosystems) in a 384-well, 15-l sample for-
mat with TaqMan universal PCR master mix (Applied Biosys-
tems). Prevalidated TaqMan primer and probe sets against
human/mouse ICAM-1, mouse GAPDH, human IL-8, and
human -actin were purchased from Applied Biosystems.
Real-time runs and data analysis were performed using the
SDS software (Applied Biosystems). Total RNA was isolated
from cells using RNeasy kits (Qiagen) and quantified using a
Nanodrop ND-1000 (Nanodrop). cDNA was produced with
Moloney murine leukemia virus reverse transcriptase from
total RNA primed with oligo(dT) (Integrated DNA Technol-
ogy) in the presence of RNasin (Promega). Semiquantitative
PCR was carried out using primers against human DJ-1 (5-
ATG TCA TGA GGC GAG CTG-3, 5-ATT TTG TCT TTA
GCA AGA GGG-3), human Cezanne (5-TGG CAG ACA
CCA TGC TGA GGG-3, 5-CGC TTT GAC TTC TCC TTC
CGC-3), human -actin (5-ATC TGG CAC CAC ACC TTC
TAC AAT GAG CTG CG-3, 5 CAT ACT CCT GCT TGC
TGA TCC ACA TC-3), mouse ICAM-1 (5-CAG TCC GCT
GTG CTT TGA GAA CTG T-3, 5-GGT ATA TCC GAG
CTT CAG AGG CAG G-3), mouse DJ-1 (5-GGA GCA GAG
GAG ATG GAG ACA GTG A-3, 5-CGC GGC TCT CTG
AGT AGC TGT AGT GA-3), and mouse GAPDH (5-CCA
CTC ACG GCA AAT TCA ACG GCA CAG-3, 5-GTG
GCA GTG ATG GCA TGG ACT GTG GTC-3). The num-
ber of cycles run on the Mastercycler (Eppendorf) was de-
pendent on the target (GAPDH/-actin, 17; DJ-1, 21; Cez-
anne/ICAM-1, 25).
Luciferase Reporter Assay—HEK293T cells transduced with
Cezanne, DJ-1, or control shRNA-containing lentivirus were
plated in 6-well dishes at 4  105/well. The following day, the
cells were transfected with either 100 ng of an SV40-positive
control or 100 ng of an NF-B-responsive luciferase reporter
construct using FuGENE 6. After 18 h, the samples were
washed with PBS, lysed with reporter lysis buffer with one
freeze/thaw cycle, and cleared using centrifugation. Luciferase
activity was assessed in each sample using an LMax micro-
plate luminometer (Molecular Devices) (19). Data are shown
as luciferase relative light units in NF-B reporter construct
containing sample normalized to a matched SV40 control.
Experiments were performed in triplicate with error bars rep-
resenting S.D. in Figs. 4 and 5.
RESULTS
Q-TOF Mass Spectrometric Identification of DJ-1-interact-
ing Proteins—To understand the mechanism of action of
DJ-1, we used Q-TOF mass spectrometry to identify binding
partners of DJ-1. Several controls were built into the experi-
mental design to minimize artifacts (Fig. 1A). First, we de-
signed our screen to identify proteins that bound DJ-1 under
oxidative and non-oxidative conditions as previously pub-
lished data highlight a role of oxidation in DJ-1 function (44).
Second, we used Park7/ MEFs to prevent endogenous DJ-1
from binding proteins of interest and decreasing assay sensi-
tivity. To start, we transfected MEFs with either FLAG-tagged
DJ-1 or FLAG-tagged C106A mutant DJ-1. Because the Cys-
106 residue is known to be oxidized and affect DJ-1 function,
the C106A mutant was used to assess the oxidative depend-
ence of binding as alanine is non-oxidizable (45). To mimic
physiologic oxidative stress, the transfected samples were
then treated with H2O2 or left untreated. After treatment, the
samples were immunoprecipitated with FLAG-agarose and
eluted with FLAG peptide. These eluates were trypsinized and
run on a Q-TOF mass spectrometer. Using a mock-trans-
fected control to remove any proteins that bound nonspecifi-
cally to the FLAG beads, we identified four proteins that
bound specifically to DJ-1 (Table 1). We selected Cezanne for
further study due to its known ability to regulate NF-B and
therefore potential to affect cell survival, a topic relevant to
cancer biology and Parkinson disease (Fig. 1B).
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DJ-1 Binds to Cezanne and Inhibits Its Deubiquitinating
Activity—To confirm the interaction between DJ-1 and Cez-
anne, we performed a series of co-immunoprecipitation ex-
periments. The interaction was first confirmed using an over-
expression system (Fig. 2A). FLAG-DJ-1 was overexpressed in
HEK293T cells in the presence or absence of V5-epitope
tagged Cezanne. After immunoprecipitation of Cezanne, DJ-1
was co-immunoprecipitated in the presence of Cezanne but
not in its absence as detected by immunoblot. To confirm an
endogenous interaction between DJ-1 and Cezanne (Fig. 2B),
we first treated HEK293T cells with H2O2 or left them un-
treated, and then immunoprecipitated endogenous DJ-1.
Western blot of the immunoprecipitation samples showed the
presence of endogenous Cezanne only in the samples where
DJ-1 was immunoprecipitated. A modest increase in this in-
teraction was detected with H2O2 treatment with one anti-
Cezanne antibody (Cez Ab1) suggesting that there might be a
form of Cezanne that is recognized by antibody 2 (Cez Ab2)
that more efficiently interacts with oxidized DJ-1.
To ascertain the effect of DJ-1 Cys-106 residue oxidation
on DJ-1/Cezanne binding, we tested the ability of overex-
pressed wild type DJ-1, non-oxidizable C106A mutant DJ-1,
or the Parkinson disease-associated L166P mutant DJ-1 to
bind endogenous Cezanne in the presence of H2O2 (Fig. 2C).
Each of the three constructs was overexpressed in HEK293T
cells treated with H2O2. As expected, lower expression of
L166P DJ-1 was seen due to its known decreased stability (46).
After immunoprecipitation for the FLAG-tagged DJ-1 pro-
teins, immunoblot analysis was performed to detect endoge-
nous Cezanne. Cezanne was co-immunoprecipitated with
wild type DJ-1 and the L166P mutant. The C106A mutant
DJ-1 co-precipitated Cezanne at a reduced level as compared
with wild type DJ-1 but more than the untransfected negative
control. This suggests that oxidation of the Cys-106 residue
enhances the interaction of DJ-1 and Cezanne in this cell type.
To identify the structural element of DJ-1 that binds Cezanne,
we produced a series of truncation mutant constructs by se-
quentially removing 100 bp off of the 3 end of the 570-bp
open reading frame of DJ-1 in a FLAG-tagged construct (Fig.
2D). This method was used due to the lack of multiple do-
main structures within DJ-1. These constructs were trans-
fected into HEK293T cells treated with H2O2, and the sam-
ples were immunoprecipitated with FLAG-agarose.
Expression of the smaller amino-terminal fragments of DJ-1
showed a progressively reduced expression, which is consist-
ent with the smaller sizes of the truncation constructs DJ-1
490T to 298T, except for DJ-1 211T, which displayed a reduc-
tion in expression that cannot be accounted for by its reduced
size, which may be due to reduced expression or decreased
stability (47). All of the truncation constructs immunoprecipi-
tated Cezanne as well as the wild type control. The efficient
interaction of 211T DJ-1 and endogenous Cezanne shows that
the amino-terminal 70 residues of DJ-1 are sufficient for in-
FIGURE 1. Overview of Q-TOF mass spectrometry results. A, schematic of
Q-TOF MS experimental design. Park7/ MEFs were transfected with
FLAG-tagged DJ-1 (Fg-DJ-1) or C106A mutant DJ-1 (Fg-C106A) and either
left untreated or treated with 100 M H2O2 for 1 h. After treatment, the
samples were immunoprecipitated with FLAG-agarose, eluted with FLAG
peptide, and analyzed by mass spectrometry. X, Y, and Z are putative inter-
acting proteins. B, peptide spectra for Cezanne, one of the four proteins
found to interact with DJ-1 (shown in Table 1).
TABLE 1
Identified DJ-1-binding proteins
Proteins found to bind DJ-1 by Q-TOF mass spectrometry after removal of nonspecific protein interactions using a control without DJ-1 overexpression are listed.
Gene Name Known functions
BBS1 Bardet-Biedl syndrome 1 Associated with syndrome characterized by
retinitis pigmentosa, polydactyly, and obesity
CLCF1 Cardiotrophin-like cytokine factor 1 Cytokine in interleukin 6 family
MTREF MTREF domain containing 1 Mitochondrial transcription termination factor
OTUD7B Cezanne/Za20d1 Deubiquitination enzyme, inhibits NF-B
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teraction with Cezanne. Residues encoded by nucleotides
298–211 might be inhibitory of this binding as their removal
results in more efficient binding, considering that the expres-
sion of DJ-1 211T is much less than DJ-1 298T (Fig. 2E).
Due to the known deubiquitinating activity of Cezanne in
vitro and the interaction between DJ-1 and Cezanne, we
produced recombinant DJ-1 and analyzed its effect on the
deubiquitination activity of Cezanne in a cell-free system
(Fig. 2F). To assess the deubiquitinating activity of Cez-
anne, we incubated synthetic ubiquitin chains with recom-
binant Cezanne in the presence or absence of DJ-1 (21).
After incubation, we analyzed the reduction in ubiquitin
chain size by immunoblot. Although Cezanne caused a de-
crease in both long and medium length ubiquitin chains
(lanes 2 and 3), DJ-1 significantly inhibited the activity of
Cezanne in a dose-dependent manner (lanes 4–6). The
inhibition of the deubiquitination activity of Cezanne by
DJ-1 was found to be specific as DJ-1 did not inhibit the
deubiquitinating activity of IsoT. Although a very modest
activation of IsoT activity on medium length ubiquitin
chains was seen with the addition of DJ-1, DJ-1 did not in-
hibit the deubiquitination activity of IsoT on long length
ubiquitin chains (lanes 7 and 8).
Identification of IL-8 and ICAM-1 as Downstream Targets
by Affymetrix Microarray—Due to the known effects of DJ-1
and Cezanne on the transcriptome, we assessed the effect
of their interaction on global transcription using microar-
ray. To identify possible downstream transcripts of DJ-1
and Cezanne, we generated a recombinant lentivirus en-
coding shRNA oligonucleotides specific for DJ-1 or Cez-
anne and mutant negative controls. After transduction of
H157 cells with recombinant lentivirus, we extracted RNA
and assessed targeted gene expression using semiquantita-
tive RT-PCR (Fig. 3A). These samples showed significant
reduction of Cezanne and DJ-1 gene expression as com-
pared with matched negative controls. The RNA was then
validated for microarray, used to produce cRNA, and hy-
bridized on a GeneChip Human Gene 1.0 ST array. The
normalized intensities for the three mutant controls were
averaged. We then filtered out any readings below 20th
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FIGURE 2. DJ-1 binds to Cezanne and inhibits the deubiquitinating ac-
tivity of Cezanne. A, overexpression co-immunoprecipitation (IP) to verify
interaction between DJ-1 and Cezanne. Cells were transfected with FLAG-
DJ-1 (Fg-DJ-1) in the presence or absence of Cezanne-V5 (Cez-V5). After im-
munoprecipitation with anti-V5-agarose, input controls and the immuno-
precipitated samples were analyzed by immunoblot (IB) with the antibodies
indicated. B, endogenous co-immunoprecipitation to verify an endogenous
interaction of DJ-1 and Cezanne. Cells were either left untreated or treated
with H2O2 and immunoprecipitated with either DJ-1 mouse monoclonal
antibody (DJ-1 mAb) or mouse control IgG. After immunoprecipitation, in-
put controls and immunoprecipitated samples were analyzed by immuno-
blot with the indicated antibodies. Cez Ab1, Cezanne antibody 1; Cez Ab2,
Cezanne antibody 2; Ab1, antibody 1; Ab2, antibody 2. C, semi-endogenous
co-immunoprecipitation to assess the effect of the C106A or L166P muta-
tion on the interaction of DJ-1 with endogenous Cezanne. Wild type and
the DJ-1 point mutants were overexpressed in HEK293T cells. Following
H2O2 treatment, the wild type and DJ-1 mutants were immunoprecipitated
with FLAG-agarose, and input controls and immunoprecipitated samples
were assessed by immunoblot. D, schematic of DJ-1 carboxyl-terminal trun-
cation mutants. E, semi-endogenous co-immunoprecipitation to identify
which portion of DJ-1 binds endogenous Cezanne. DJ-1 truncation mutants
were overexpressed in HEK293T cells. After H2O2 treatment, the samples
were immunoprecipitated with FLAG-agarose, and immunoblot was used
to assess the input controls and immunoprecipitated samples. F, in vitro
deubiquitination assay. Synthetic ubiquitin chains were incubated with re-
combinant Cezanne (rCezanne) or IsoT (rIsoT) in the presence or absence of
DJ-1 at 37 °C in assay buffer. After incubation, the samples were analyzed
for ubiquitin chain degradation by immunoblot.
FIGURE 3. Affymetrix microarray analysis of cells with DJ-1 or Cezanne
shRNA. A, semiquantitative RT-PCR confirming reduced expression with
DJ-1 (shDJ-1) or Cezanne (shCez3 and shCez4) shRNA and control shRNAs
(mutDJ-1, MutCez3, and MutCez4) in appropriate samples transduced with
lentivirus. B, Venn diagram showing the number of genes up-regulated (up-
reg) or down-regulated (downreg) with DJ-1 or Cezanne shRNA. The raw
intensities of replicate samples were averaged, and filters were set for 20
percentile intensity using a cutoff of 1.7-fold as compared with the aver-
aged negative control sample. C, graph showing the raw intensity results
from the microarray analysis for IL-8 and ICAM-1, the only two characterized
targets differentially regulated by DJ-1 and Cezanne.
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ing the DJ-1 and Cezanne knockdown samples against the
control using a 1.7-fold change cutoff. Due to our interest
in genes regulated by both DJ-1 and Cezanne, we cross-
referenced the lists of genes regulated by DJ-1 or Cezanne
(Fig. 3B). This search showed that IL-8 and ICAM-1 were
reciprocally controlled by DJ-1 and Cezanne (Fig. 3C). In-
genuity pathway analysis (Ingenuity Systems) was used to
identify any role of Cezanne in regulation of Nrf2 down-
stream targets. Out of the 43 Nrf2 targets assessed, none of
the targets were changed significantly enough to meet our
-fold change cut off, suggesting no or little role for Cez-
anne in the regulation of Nrf2 (supplemental Fig. S1).
DJ-1 and Cezanne Regulate IL-8 and ICAM-1 through Mod-
ulation of NF-B Nuclear Localization—To verify the mi-
croarray results, we used real-time PCR to verify the regula-
tion of IL-8 and ICAM-1 by DJ-1 and Cezanne. After
transducing H157 cells with control, DJ-1, or Cezanne
shRNA, real-time PCR was performed for human -actin,
IL-8, and ICAM-1 (Fig. 4A). This analysis confirmed a sig-
nificant decrease in IL-8 and ICAM-1 expression with DJ-1
shRNA and an increased expression of these genes with
Cezanne shRNA, consistent with the Affymetrix results. To
assess the effect of DJ-1 and Cezanne on IL-8 secretion,
supernatants from lentiviral transduced H157 cell lines
were analyzed using IL-8 ELISA. The datum showed that
DJ-1 shRNA decreased IL-8 production, whereas Cezanne
shRNA increased IL-8, matching the observations seen at
the transcript level (Fig. 4B). Immunoblot analysis of trans-
duced H157 cells treated with TNF showed a decrease in
ICAM-1 protein levels with DJ-1 shRNA and an increase in
ICAM-1 levels with Cezanne shRNA consistent with the
microarray, real-time PCR, and IL-8 ELISA data (Fig. 4C).
As NF-B is a known target of Cezanne as well as an in-
ducer of IL-8 and ICAM-1 transcription, we made several
attempts at analyzing the effects of DJ-1 and Cezanne on
NF-B activity using luciferase reporter constructs. Using
overexpression of DJ-1 in this system yielded no significant
difference in NF-B reporter activity, most likely due to
the high endogenous expression of DJ-1 (not shown). We
then switched to an endogenous system using shRNA-me-
diated knockdown of DJ-1, which resulted in a modest but
reproducible decrease in NF-B reporter activity with re-
duced DJ-1 levels (supplemental Fig. S2). We next used a
more physiologic assay and evaluated the nuclear localiza-
tion of NF-B in DJ-1 and Cezanne shRNA-treated H157
cells. After transduction with DJ-1 or Cezanne shRNA, nu-
clear and cytoplasmic fractions were collected and ana-
lyzed by immunoblot. Immunoblot for the p65 NF-B sub-
unit showed that DJ-1 shRNA caused a decrease in nuclear
p65 as compared with the shRNA control, whereas Cez-
anne shRNA-treated samples caused increased nuclear p65
(Fig. 4D). This effect of DJ-1 on NF-B nuclear localization
also affects the transcriptional activity of NF-B. Immuno-
blots for histone deacetylase 2 (HDAC2) and -actin were
used to show equal loading and nuclear fraction purity,
respectively. Due to the known pro-survival effect of in-
creased DJ-1 expression in cancer cells undergoing chemo-
therapeutic treatment (16), we assessed the effect of DJ-1
and Cezanne shRNA on chemotherapeutic-induced H157
cell death. We treated lentiviral transduced H157 cells with
Paclitaxel and MEK inhibitor for 24 h, a combination treat-
ment shown to be effective in H157 cells (16). After treat-
ment, cell death was analyzed using a histone-based cell
death ELISA (Roche Applied Science). Untreated samples
were used to account for homeostatic cell turnover, and
-fold changes in cell death were calculated as compared
with the mutant shRNA control. A statistically significant
increase in cell death was seen with DJ-1 shRNA, whereas a
decrease was seen in the Cezanne shRNA samples (Fig. 4E).
ICAM-1 Is Regulated by DJ-1 and Cezanne in Primary
MEFs—The above results were obtained with a transformed
cell line; thus it was important to analyze the expression of
ICAM-1 in a primary cell line such as MEFs. Only ICAM-1
was assayed because mouse cells do not express IL-8.
Park7/ and Park7/ MEFs were treated with increasing
levels of TNF to induce ICAM-1 expression. After treat-
FIGURE 4. DJ-1 and Cezanne regulate IL-8 and ICAM-1 through modula-
tion of NF-B nuclear localization. A, real-time PCR for IL-8 and ICAM-1 in
H157 cells treated with DJ-1 and Cezanne shRNA. The 		Ct method was
used to calculate -fold changes based on differences in cycle number as
compared with matched -actin controls and mutant shRNA (shmut) sam-
ples. Error bars denote S.D. of three separate samples within an experiment
repeated three times. B, transduced H157 cultures were incubated with
fresh media for 6 h, supernatants were collected, and secreted IL-8 levels
were assessed by ELISA. Error bars denote S.D. of three separate samples
within an experiment repeated three times. C, H157 cultures transduced
with lentivirus were treated with increasing doses of TNF for 6 h and as-
sessed for ICAM-1 protein levels by immunoblot. Norm, normal. D, nuclear
and cytoplasmic (Cyto) fractions collected from transduced H157 cultures
were assessed for nuclear p65 by immunoblot. HDAC2 and -actin were
used as a loading control and fractionation control, respectively. E, trans-
duced H157 cultures were treated with 500 nM Paclitaxel and 10 M U0126
for 24 h. After treatment, the samples were collected and tested for cell
death using a histone-based cell death ELISA. Untreated samples were used
to control for cell turnover. Data were expressed as -fold change as com-
pared with mutant shRNA control samples. Error bars denote S.D. of data
from three normalized experiments.
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ment, the levels of ICAM-1, DJ-1, and GAPDH were assessed
by semiquantitative RT-PCR (Fig. 5A). DJ-1 was expressed in
Park7/ but not Park7/ cells, and the expression of
ICAM-1 was reduced in the Park7/ cells relative to GAPDH
control. This finding confirms the positive regulatory role of
DJ-1 in ICAM-1 transcript expression in primary MEFs. To
assess the effect of Cezanne on ICAM-1 expression in MEFs,
ICAM-1 expression was measured by real-time PCR in
TNF-treated or untreated Park7/ MEFs transduced with
Cezanne shRNA or a matched mutant control (Fig. 5B). Cez-
anne shRNA caused an increase in ICAM-1 expression in
TNF-treated MEFs. These data confirmed an activating role
of DJ-1 and an inhibitory role of Cezanne on ICAM-1 expres-
sion in MEFs.
DISCUSSION
Due to the prominent link between DJ-1 genetic inactiva-
tion and early onset Parkinson disease in humans, a large por-
tion of the DJ-1 literature has focused on the role of DJ-1 in
neuronal cell death (48, 49). That work uncovered a broader
role of DJ-1 in cell survival outside of the nervous system.
DJ-1 has been shown to be a central molecule in cell survival
by positively regulating Nrf2-dependent detoxification path-
ways (19), inhibiting p53-mediated cell cycle checkpoints (20)
possibly via caspase-6 (51), and inducing Akt activity through
the inhibition of Phosphatase and Tensin homolog (PTEN)
(15). Likely due to its effects on cell survival, DJ-1 has been
found to be dysregulated in several human cancers (8, 11, 12,
16). Increased expression of DJ-1 has been shown in a number
of human carcinomas and is associated with negative survival
outcomes and resistance to chemotherapeutics.
In this study, we identify a novel pathway by which DJ-1
modulates IL-8 and ICAM-1 levels through the regulation
of Cezanne activity and NF-B nuclear localization. Using
a proteomic approach, we identify four binding partners of
DJ-1. One of these DJ-1 binding partners, Cezanne, is a
member of the A20 family of immunoregulatory deubiq-
uitinating enzymes. Similar to A20, Cezanne is known to
inhibit NF-B through modulation of the ubiquitination
status of RIP-1 and TRAF6 (21, 22). NF-B, a cell survival-
associated transcription factor, is known to be dysregulated
in a variety of cancer types including NSCLC (24–26, 50).
After confirming endogenous interaction of DJ-1 and Cez-
anne, we showed that the DJ-1/Cezanne interaction is en-
hanced by oxidation of the Cys-106 residue of DJ-1 and
that the amino terminus of DJ-1 is sufficient to mediate
this interaction. The interaction also leads to the inhibition
of the deubiquitinating activity of Cezanne in vitro. We
used microarray analysis to identify the transcriptional tar-
gets and thus the pathways regulated by the DJ-1/Cezanne
interaction. DJ-1 and Cezanne shRNA were found to recip-
rocally regulate ICAM-1 and IL-8. As ICAM-1 and IL-8 are
targets of NF-B, this datum suggests a role of DJ-1 and
Cezanne in NF-B-mediated transcription, whereas no role
of Cezanne was seen in Nrf2-mediated transcription as
downstream targets of Nrf2 were unchanged in the pres-
ence of Cezanne shRNA. This link between DJ-1 and
NF-B was confirmed as nuclear p65 was found to be de-
creased in the presence of DJ-1 shRNA, making this work
the first to identify DJ-1 as a positive regulator of
NF-B.
IL-8 is released by a subset of NSCLC cell lines in response
to chemotherapy treatment (34). As IL-8 is a pro-survival sig-
nal, this IL-8 release can inhibit chemotherapeutic efficacy
(32). Acting in an autocrine or paracrine fashion to activate
NF-B through stimulation of the CXCR1 receptor, IL-8
causes its continued release, completing a pro-survival-posi-
tive feedback loop (34, 35). Through inhibition of DJ-1 or ac-
tivation of Cezanne, we can disrupt this IL-8-controlled pro-
survival loop, thus increasing the sensitivity of IL-8 secreting
tumors to chemotherapeutics (36). Aside from its effects on
cell survival, IL-8 has been shown to promote angiogenesis,
cancer progression, invasion, and metastasis (27, 29–33).
Concordant with IL-8, ICAM-1 dysregulation has been asso-
ciated with tumor progress, invasion, and metastasis (33, 40,
41). Through regulation of IL-8 and ICAM-1, DJ-1 and Cez-
anne may impact angiogenesis and tumor progression, lead-
ing to changes in tumor growth and survival in in vivo cancer
models separate from their effects on cell survival and drug
efficacy seen in vitro.
As a whole, we identify DJ-1 as a positive regulator of can-
cer cell survival via a cell type-specific pathway that controls
IL-8 and ICAM-1 expression. The pro-cancer activities of
these molecules are well documented. However, IL-8 is also a
potent chemotactic molecule for infiltrating inflammatory
cells such as neutrophils. Therefore IL-8 has manifold roles
during carcinogenesis. In an autocrine role, it contributes to
cell, survival but in a cancer cell-autonomous role, it facili-
tates the recruitment of infiltrating inflammatory cells such as
FIGURE 5. ICAM-1 is regulated by DJ-1 and Cezanne in primary MEFs. A,
ICAM-1 expression is decreased in Park7/ MEFs. Park7/ and Park7/
MEFs were plated and treated with 0, 10, or 50 ng/ml TNF for 6 h. After
treatment, RNA was harvested, and ICAM-1 levels were assessed by RT-PCR
using DJ-1 to verify the genotype and GAPDH to show equal loading. B, real-
time PCR assessing the effects of Cezanne shRNA on ICAM-1 expression in
primary MEFs. Park7/ MEFs were transduced with Cezanne or mutant
control shRNA (shmut). The cultures were treated with 50 ng/ml TNF for
6 h, RNA was harvested, and real-time PCR was performed to assess ICAM-1
expression and induction. -Fold changes were calculated by the 		Ct
method using GAPDH as a reference control in matched samples. Error bars
denote S.D. of three normalized experiments.
DJ-1 and Cezanne Regulate IL-8 and ICAM-1 through NF-B
4104 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 6 • FEBRUARY 11, 2011
neutrophils. Future studies will need to be conducted to con-
firm that this pathway is mediated through the deubiquitina-
tion of RIP-1 and TRAF6 by Cezanne as well as identify other
NF-B targets regulated by DJ-1 under cell stimulation. Fi-
nally, mouse tumor models will be necessary to examine the
effects of DJ-1 and Cezanne expression on tumor growth and
inflammation in vivo.
Due to the central role of DJ-1 in transcriptional regulation,
identification of DJ-1 inhibitors may lead to novel treatment
regimens that modulate cancer hallmarks including cancer
cell growth, survival, angiogenesis, progression, invasion, and
metastasis as well as boosting the efficacy of current
chemotherapeutics.
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